Sufentanil sublingual tablet system vs. intravenous patient-controlled analgesia with morphine for postoperative pain control: a randomized, active-comparator trial
| Autor: | Timothy I. Melson, Alparslan Turan, Mark A. Evashenk, Harold S. Minkowitz, David L Boyer, Yu-Kun Chiang, Pamela P. Palmer |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Adult
Male medicine.medical_specialty Sufentanil sublingual tablet system medicine.medical_treatment Analgesic Knee replacement Administration Oral sublingual patient-controlled analgesia Patient satisfaction oxygen desaturation medicine Humans Adverse effect Infusions Intravenous Aged Pain Measurement Aged 80 and over Pain Postoperative Morphine Patient-controlled analgesia business.industry onset of analgesia Analgesia Patient-Controlled Middle Aged adverse events Surgery Analgesics Opioid Drug Combinations Anesthesiology and Pain Medicine Treatment Outcome Opioid Anesthesia opioid Female Original Article business postoperative pain Intravenous Patient-Controlled Analgesia medicine.drug Tablets |
| Zdroj: | Pain Practice |
| ISSN: | 1533-2500 |
| Popis: | Background Problems with intravenous patient-controlled analgesia (IV PCA) are well known, including invasive route of delivery and pump programming errors. The primary objective of this study was to evaluate patient satisfaction with a novel sublingual sufentanil PCA system (sufentanil sublingual tablet system 15 mcg with a 20-minute lockout interval; SSTS) to IV PCA morphine sulfate 1 mg with a 6-minute lockout interval (IV PCA MS) for the management of acute postoperative pain. Methods This was a randomized, open-label, 48-hour non-inferiority study with optional extension to 72 hours at 26 U.S. sites enrolling patients scheduled for elective major open abdominal or orthopedic (hip or knee replacement) surgery. The primary outcome measure was the proportion of patients who responded “good” or “excellent” (collectively “success”) at the 48-hour timepoint on the Patient Global Assessment of method of pain control (PGA48). Results A total of 357 patients received study drug and 78.5% vs. 65.6% of patients achieved PGA48 “success” for SSTS vs. IV PCA MS, respectively, demonstrating non-inferiority (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|